| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5701120 | European Journal of Surgical Oncology (EJSO) | 2016 | 22 Pages |
Abstract
Adding cetuximab to first-line FOLFIRI appears to improve clinical outcomes and R0 resection rates in KRAS wt and RAS wt mCRC patients with LLD as well as in those with non-LLD.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
C.-H. Köhne, G. Poston, G. Folprecht, F. Ciardiello, P. Ronga, F. Beier, E. Van Cutsem,